 |
|
Event Calender
| |
|
This is a selection of high-class scientific events cardiovascular risk management in 2008. You may print or download this page to keep it on your desk.
|
|
|
|
|
ESC Nice
|
|
|
Date:
|
13 May to 16 May 2008
|
|
Location:
|
Nice, France
|
|
Description:
|
The XVII. European Stroke Conference (ESC) was aimed at researchers and specialised clinic personnel. The programme presented current events in stroke research along with a broad range of workshops and presentations for an intercultural exchange of experience in the prevention and treatment of stroke. Read more about the ESC Nice: http://www.eurostroke.org/
|
|
Bayer Activities:
|
Bayer Schering Pharma presented the benefits of Aspirin cardio in the prevention of primary and secondary stroke and the latest ONTARGET outcomes regarding Pritor/Kinzal (telmisartan) at its exhibition stand No 101.
read more
|
|
|
|
|
WCC Buenos Aires
|
|
|
Date:
|
18 May to 21 May 2008
|
|
Location:
|
Buenos Aires, Argentina
|
|
Description:
|
Cardiologists and related specialists, members of heart foundations and healthcare professionals from over 100 countries met at the World Congress of Cardiology 2008 (WCC). Latest scientific advances on the management of cardiovascular diseases have been discussed by delegates from developed and developing countries. Read more about the WCC Buenos Aires: http://www.worldcardiocongress.org/
|
|
Bayer Activities:
|
In addition to a joint satellite symposium with Aspirin Cardio and Adalat which was organized by Bayer Schering Pharma [Room 6, Yellow Pavilion] the latest scientific data on the topics Peripheral Artery Occlusive Disease (CLIPS study), Priority among Preventative Services and Aspirin responsiveness have been presented in the Green Pavilion of La Rural Convention & Exhibition Centre.
CVRM Programme
Furthermore Bayer Schering Pharma presented at its exhibition stand No 302 latest data regarding primary and secondary prevention with Aspirin Cardio, BP control and CVD protection with Adalat, alone or in combination, diabetes management & CV benefits with Glucobay and inhaled treatment of PAH with Ventavis.
read more
|
|
|
|
|
ESC Munich
|
|
|
Date:
|
30 August to 3 September 2008
|
|
Location:
|
Munich, Germany
|
|
Description:
|
The European Society of Cardiology (ESC) showed the latest findings in the diagnosis, management and treatment of cardiovascular disease. Physicians from around the world met in this unique forum in order to discuss the latest scientific developments in the area of cardiovascular medicine. Highlights included interactive educational sessions with live transmissions from throughout Europe, combining theoretical knowledge with practical skills Read more about the ESC Munich: http://www.escardio.org/
|
|
Bayer Activities:
|
Bayer Schering Pharma sponsored a satellite symposium concerning Cardiovascular Risk Management and another for Aspirin Cardio. The latest scientific data on Aspirin Cardio have been presented together with the entire cardiovascular risk management portfolio at the Bayer Schering Pharma fair stand No B2-C403.
read more
|
|
|
|
|
EASD Rome
|
|
|
Date:
|
7 September to 11 September 2008
|
|
Location:
|
Rome, Italy
|
|
Description:
|
he European Association for the Study of Diabetes (EASD) united scientists, physicists, laboratory technicians, nurses and students from around the world. The 44th Annual Conference presented the latest status of research and the newest developments in the area of diabetes and related topics. Symposia, lectures and presentations were the components of the programme. Read more about the EASD Rome: http://www.easd2008.org/
|
|
Bayer Activities:
|
At fair stand H3.35 in hall 3 Bayer Schering Pharma presented the range of cardiovascular benefits of Aspirin Cardio in the treatment of diabetes together with latest data regarding the Oral Antidiabetic Drug Glucobay and the well-known diabetes self monitoring devices of Bayer HealthCare.
|
|
|
|
|
|
|
|
|
 |
|
 |
"After five years the external data monitoring board asked that we terminate the study because of a striking, very extreme benefit of aspirin. Aspirin® reduced the risk of a first heart attack by 44 percent, and this was quite an earthshaking finding at that time."
|
|
 |
|
|
Aspirin Cardio® Screensaver
Out now: The new Aspirin Cardio® Screensaver.
Download here...
|
|
 |
|
|
Aspirin Cardio® Trailer
Click here to download the Aspirin Cardio® Trailer "Did you know..."
|
|
|
|
|
|
|
|
|
